Combined 1p/19q loss in oligodendroglial tumors: Predictive or prognostic biomarker?

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 6933-6937

  Weller, Michael ^a   Berger, Hilmar ^b   Hartmann, Christian ^c   Schramm, Johannes ^d   Westphal, Manfred ^e   Simon, Matthias ^d   Goldbrunner, Roland ^f   Krex, Dietmar ^g   Steinbach, Joachim P ^a   Ostertag, Christoph B ^h   Loeffler, Markus ^b   Pietsch, Torsten ^d   Von Deimling, Andreas ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF HAMBURG   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENOTOXICITY; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROSURGERY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 37249021342     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0573     Document Type: Article

References (10)

1. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
2. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-61.
3. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000;48:825-30.
4. Intergroup Radiation Therapy Oncology Group Trial 9402; Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707-14.
5. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-22.
6. Jeuken J, Cornelissen S, Boots-Sprenger S, et al. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 2006;8:433-43.
7. Hartmann C, Müller W, Lass U, et al. Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 2005;64:10-4.
8. R Development Core Team. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2005.
9. Kanner AA, Staugaitis SM, Castilla EA, et al. The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg 2006;104:542-50.
10. Mariani L, Deiana G, Vassella E, et al. Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol 2006;24:4758-63.